(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 15.64% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Transmedics Group's revenue in 2026 is $668,468,000.On average, 15 Wall Street analysts forecast TMDX's revenue for 2026 to be $26,288,961,182, with the lowest TMDX revenue forecast at $24,996,965,279, and the highest TMDX revenue forecast at $27,415,903,394. On average, 15 Wall Street analysts forecast TMDX's revenue for 2027 to be $30,938,898,126, with the lowest TMDX revenue forecast at $29,203,753,870, and the highest TMDX revenue forecast at $33,314,145,559.
In 2028, TMDX is forecast to generate $35,923,450,220 in revenue, with the lowest revenue forecast at $32,503,440,669 and the highest revenue forecast at $40,604,594,795.